A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC

Abstract Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies; thus we evaluated it in combination with Taxol, a chemotherapeutic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Leleesha Samaraweera, Alfred Adomako, Alicia Rodriguez-Gabin, Hayley M. McDaid
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/8bf6e32804f94f5480e8b18e2a01b3ef
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!